Smrkolj Tomaž, Gubina Borut, Bizjak Jure, Kumer Kristina, Fabjan Teja, Osredkar Joško
Department of Urology, Ljubljana University Medical Centre, Slovenia.
Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, Slovenia.
Adv Clin Exp Med. 2017 Oct;26(7):1085-1090. doi: 10.17219/acem/65432.
The α-fetoprotein receptor (RECAF) is a proposed novel tumor marker for detecting several different types of tumors, including prostate cancer (PCa).
The aim of the study was to evaluate RECAF in discriminating benign prostatic conditions from PCa and to compare it with prostate-specific antigen (PSA).
A total of 64 patients with elevated serum PSA levels and/or abnormal digital rectal examination of the prostate referred to a tertiary center for transrectal ultrasound (TRUS) biopsy of the prostate were prospectively enrolled in the study from January 2009 to April 2010. Serum RECAF, total PSA (tPSA) and free PSA (fPSA) concentrations were measured. The results were correlated with histopathologic findings using the Mann-Whitney U test and Kruskal-Wallis χ2 test.
The median RECAF concentration was 5.34 U/L in the benign pathology group of patients and 4.72 U/L in the malignant pathology group. The difference was not statistically significant. RECAF density, tPSA and fPSA concentrations and tPSA density were significantly different between the benign and malignant pathology groups (p = 0.033, p = 0.000, p = 0.002 and p = 0.000, respectively). RECAF concentration and RECAF density did not differ significantly in the subgroups of PCa patients stratified according to Gleason score, predominant primary Gleason grade or maximum primary Gleason grade, but in predominant secondary Gleason grade and maximum secondary Gleason grade, significant differences were found (p = 0.007 and p = 0.004, respectively).
The results of the study did not confirm the RECAF tumor marker as an alternative way to discriminate between groups of patients with benign prostatic conditions and PCa, and its concentration and density do not differ among PCa histopathologic groups.
甲胎蛋白受体（RECAF）是一种被提议用于检测多种不同类型肿瘤（包括前列腺癌（PCa））的新型肿瘤标志物。
本研究旨在评估RECAF在鉴别前列腺良性疾病与PCa方面的作用，并将其与前列腺特异性抗原（PSA）进行比较。
2009年1月至2010年4月，前瞻性纳入了64例血清PSA水平升高和/或前列腺直肠指检异常并被转诊至三级中心进行经直肠超声（TRUS）引导下前列腺穿刺活检的患者。检测血清RECAF、总PSA（tPSA）和游离PSA（fPSA）浓度。使用Mann-Whitney U检验和Kruskal-Wallis χ2检验将结果与组织病理学结果进行关联分析。
良性病理组患者的RECAF浓度中位数为5.34 U/L，恶性病理组为4.72 U/L。差异无统计学意义。良性和恶性病理组之间的RECAF密度、tPSA和fPSA浓度以及tPSA密度存在显著差异（分别为p = 0.033、p = 0.000、p = 0.002和p = 0.000）。根据Gleason评分、主要原发Gleason分级或最大原发Gleason分级分层的PCa患者亚组中，RECAF浓度和RECAF密度无显著差异，但在主要继发Gleason分级和最大继发Gleason分级中，发现有显著差异（分别为p = 0.007和p = 0.004）。
本研究结果未证实RECAF肿瘤标志物可作为鉴别前列腺良性疾病患者组与PCa患者组的替代方法，且其浓度和密度在PCa组织病理学组之间无差异。
